Clinical Trials · NCT03989232
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 961
- Start date
- Jun 2019
- Locations
- 129 sites, 11 countries
- Primary endpoint
- Change in HbA1c